Cramer Rosenthal Mcglynn LLC Takes $7.70 Million Position in Omnicell, Inc. (NASDAQ:OMCL)

Cramer Rosenthal Mcglynn LLC purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 173,031 shares of the company's stock, valued at approximately $7,703,000. Cramer Rosenthal Mcglynn LLC owned approximately 0.37% of Omnicell as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Omnicell by 93.3% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock valued at $64,573,000 after purchasing an additional 699,925 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Omnicell by 32.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock valued at $67,951,000 after acquiring an additional 377,883 shares during the period. Renaissance Technologies LLC boosted its holdings in Omnicell by 79.3% in the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company's stock valued at $20,316,000 after acquiring an additional 201,831 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Omnicell by 46.1% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,687 shares of the company's stock worth $19,130,000 after purchasing an additional 135,650 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Omnicell in the 4th quarter valued at about $5,372,000. Institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Benchmark reiterated a "buy" rating and set a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. cut their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Bank of America reduced their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday, January 6th. Wells Fargo & Company reduced their price target on shares of Omnicell from $40.00 to $38.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Finally, StockNews.com upgraded shares of Omnicell from a "hold" rating to a "buy" rating in a research report on Tuesday, April 15th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $50.67.

Omnicell Stock Up 2.3 %

NASDAQ OMCL traded up $0.69 on Wednesday, reaching $30.61. The company had a trading volume of 169,603 shares, compared to its average volume of 533,472. The company's fifty day moving average is $34.85 and its 200-day moving average is $41.10. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 113.37, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, research analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.